Menu Search
Equities

Egetis Therapeutics AB (publ)

EGTX:STO

Egetis Therapeutics AB (publ)

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (SEK)4.51
  • Today's Change-0.08 / -1.74%
  • Shares traded244.35k
  • 1 Year change+3.44%
  • Beta0.9853
Data delayed at least 15 minutes, as of Sep 23 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Sep-23
  • 20-Jun-24
  • 18-Jul-24
  • 15-Aug-24
  • 19-Sep-24
Select bar for recommendation details.
Recommendations19-Sep-24
Buy1
Outperform3
Hold1
Sell0
Strong Sell0

Share price forecast in SEK

The 5 analysts offering 12 month price targets for Egetis Therapeutics AB (publ) have a median target of 13.00, with a high estimate of 16.60 and a low estimate of 11.00. The median estimate represents a 188.25% increase from the last price of 4.51.
High268.1%16.60
Med188.2%13.00
Low143.9%11.00

Earnings history & estimates in SEK

On Aug 22, 2024, Egetis Therapeutics AB (publ) reported 2nd quarter 2024 losses of -0.20 per share. This result exceeded the -0.300 consensus loss of the 4 analysts covering the company and exceeded last year's 2nd quarter results by 33.33%.
The next earnings announcement is expected on Nov 08, 2024.
Average growth rate+8.33%
Egetis Therapeutics AB (publ) reported annual 2023 losses of -1.30 per share on Feb 22, 2024.
Average growth rate-40.51%
More ▼

Revenue history & estimates in SEK

PledPharma AB had 2nd quarter 2024 revenues of 13.90m. This bettered the 11.88m consensus of the 4 analysts covering the company. This was 104.41% above the prior year's 2nd quarter results.
Average growth rate+56.50%
PledPharma AB had revenues for the full year 2023 of 57.60m. This was 154.87% above the prior year's results.
Average growth rate+14.32%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.